ClinicalTrials.gg
CompletedNCT01017029EVERHEARTUpdated Jan 12, 2015Results posted

Everolimus in de Novo Heart Transplant Recipients

A Phase 4 interventional study of Everolimus and Mycophenolate mofetil + Everolimus in Cardiac Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-01-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study, in de novo heart transplant patients, is to evaluate whether delayed introduction of everolimus reduces the occurrence of wound healing problems, pericardial and/or pleural effusion and early acute renal insufficiency, as compared with immediate introduction of everolimus, in the firs six months after heart transplantation.

02

Conditions studied

  • Cardiac Transplantation
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female cardiac transplant candidates 18-65 years of age undergoing primary heart transplantation.
  • (GFR by MDRD) ≥ 40 mL/min/1.73 m2 at randomization

Exclusion criteria

Exclusion criteria:

  • Patients who are recipients of multiple solid organ transplants
  • Patients who are -positive or positive (PCR only) or B-surface antigen positive;
  • Presence of Donor/Recipients serological mismatch for or C;
  • Recipients of organ from donors positive for Hepatitis B-surface antigen;
  • Panel Reactive Antibodies (cytotoxicity method) > 30%.
  • Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (actual)

Study arms

  • Active comparator
    Immediate introduction of everolimus

    Drug: Everolimus

  • Experimental
    Delayed introduction of everolimus

    delayed introduction) + Cyclosporin + steroids

    Drug: Mycophenolate mofetil + Everolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Participants With at Least One Occurrence of Safety Composite Endpoint After 6 Months by Treatment Group

    Comparison of 6-month cumulative incidence of safety composite endpoint (wound healing delay) related to initial transplant surgery, pleural/pericardial effusions and occurrence of acute renal insufficiency, defined as estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2, between delayed everolimus arm and immediate everolimus arm

    Time frame: 6 months

Secondary outcomes

  1. Partcipants With at Least One Occurrence of Each Safety Composite Endpoint Event After 6 Months by Treatment Group

    Time frame: 6 months

  2. Hazard Cox's Model Analysis of Pericardial/Pleural Effusions

    Pericardial effusions: any pericardial effusion defined as at least moderate (i.e. measuring at least 2.0 cm in diastole, in the point of largest distance between the pericardial leaflets), with or without signs of hemodynamic compromise, or leading to drainage or to prolonged hospitalization. Pleural effusions: need for surgical drainage tubes for longer than 7 days after surgery and subsequent pleural effusions leading to drainage. CI = confidence interval, HR = hazard ratio, MDRD = Modification of Diet in Renal Disease

    Time frame: 6 months

  3. Absolute and Percent Frequencies of Patients With LDL ≥ 100 mg/mL at 1, 3 and 6 Months, by Treatment Group

    LDL = low density lipoprotein

    Time frame: 6 months

  4. Participants With CMV Infection and CMV Syndrome/Disease After 6 Months by Treatment Group

    CMV infection is defined as pp65 antigenemia or DNAemia

    Time frame: 6 months

  5. Participants With at Least One Occurrence of Composite Treatment Failure Events

    Comparison of 6-months cumulative incidence of composite treatment failure events (BPAR ≥ 2R, rejection with hemodynamic compromise, graft loss, or death) between delayed everolimus arm and immediate everolimus arm

    Time frame: 6 months

07

Results

Posted Dec 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneImmediate Introduction of EverolimusDelayed Introduction of Everolimus
Started8992
Completed8590
Not completed42
Withdrew: Lost to follow-up10
Withdrew: Administrative problem01
Withdrew: Death31

Outcome measures

PrimaryParticipants With at Least One Occurrence of Safety Composite Endpoint After 6 Months by Treatment Group

Comparison of 6-month cumulative incidence of safety composite endpoint (wound healing delay) related to initial transplant surgery, pleural/pericardial effusions and occurrence of acute renal insufficiency, defined as estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2, between delayed everolimus arm and immediate everolimus arm

Time frame:
6 months
Reported as:
Number · participants
Participants With at Least One Occurrence of Safety Composite Endpoint After 6 Months by Treatment Group
participantsImmediate Introduction of EverolimusDelayed Introduction of Everolimus
Participants With at Least One Occurrence of Safety Composite Endpoint After 6 Months by Treatment Group40 (34.60 to 55.30)30 (23.00 to 42.20)
Statistical analysis
  • Immediate Introduction of Everolimus vs Delayed Introduction of Everolimus · Regression, Cox · p = 0.1043 · Hazard ratio (hr): 1.482 · 95% CI 0.922 to 2.383
SecondaryPartcipants With at Least One Occurrence of Each Safety Composite Endpoint Event After 6 Months by Treatment Group
Time frame:
6 months
Reported as:
Number · participants
Partcipants With at Least One Occurrence of Each Safety Composite Endpoint Event After 6 Months by Treatment Group
participantsImmediate Introduction of EverolimusDelayed Introduction of Everolimus
Wound healing complication10 (4.7 to 17.8)8 (2.9 to 14.50)
Pleural effusion1 (0.00 to 3.30)1 (0.00 to 3.20)
Pericardial effusion30 (23.90 to 43.50)18 (11.50 to 27.70)
eGFR ≤ 30 mL/min/1.73 m27 (2.30 to 13.50)8 (2.90 to 14.50)
SecondaryHazard Cox's Model Analysis of Pericardial/Pleural Effusions

Pericardial effusions: any pericardial effusion defined as at least moderate (i.e. measuring at least 2.0 cm in diastole, in the point of largest distance between the pericardial leaflets), with or without signs of hemodynamic compromise, or leading to drainage or to prolonged hospitalization. Pleural effusions: need for surgical drainage tubes for longer than 7 days after surgery and subsequent pleural effusions leading to drainage. CI = confidence interval, HR = hazard ratio, MDRD = Modification of Diet in Renal Disease

Time frame:
6 months
Reported as:
Number · participants
Hazard Cox's Model Analysis of Pericardial/Pleural Effusions
participantsImmediate Introduction of EverolimusDelayed Introduction of Everolimus
Hazard Cox's Model Analysis of Pericardial/Pleural Effusions3018
Statistical analysis
  • Immediate Introduction of Everolimus vs Delayed Introduction of Everolimus · Regression, Cox · p = 0.0398 · Hazard ratio (hr): 1.847 · 95% CI 1.029 to 3.315
SecondaryAbsolute and Percent Frequencies of Patients With LDL ≥ 100 mg/mL at 1, 3 and 6 Months, by Treatment Group

LDL = low density lipoprotein

Time frame:
6 months
Reported as:
Number · participants
Absolute and Percent Frequencies of Patients With LDL ≥ 100 mg/mL at 1, 3 and 6 Months, by Treatment Group
participantsImmediate Introduction of EverolimusDelayed Introduction of Everolimus
Month 141 (35.70 to 56.40)38 (31.60 to 51.90)
Month 337 (32.60 to 53.50)37 (30.20 to 50.20)
Month 634 (28.10 to 48.30)36 (29.20 to 49.10)
SecondaryParticipants With CMV Infection and CMV Syndrome/Disease After 6 Months by Treatment Group

CMV infection is defined as pp65 antigenemia or DNAemia

Time frame:
6 months
Reported as:
Number · participants
Participants With CMV Infection and CMV Syndrome/Disease After 6 Months by Treatment Group
participantsImmediate Introduction of EverolimusDelayed Introduction of Everolimus
CMV infections46 (41.30 to 62.10)63 (59.00 to 78.00)
CMV syndrome/disease3 (0.00 to 7.10)6 (1.50 to 11.60)
Statistical analysis
  • Immediate Introduction of Everolimus vs Delayed Introduction of Everolimus · Fisher Exact · p = 0.0234
SecondaryParticipants With at Least One Occurrence of Composite Treatment Failure Events

Comparison of 6-months cumulative incidence of composite treatment failure events (BPAR ≥ 2R, rejection with hemodynamic compromise, graft loss, or death) between delayed everolimus arm and immediate everolimus arm

Time frame:
6 months
Reported as:
Number · participants
Participants With at Least One Occurrence of Composite Treatment Failure Events
participantsImmediate Introduction of EverolimusDelayed Introduction of Everolimus
Participants With at Least One Occurrence of Composite Treatment Failure Events33 (27.00 to 47.10)26 (19.10 to 37.50)
Statistical analysis
  • Immediate Introduction of Everolimus vs Delayed Introduction of Everolimus · Regression, Cox · p = 0.1966 · Hazard ratio (hr): 1.403 · 95% CI 0.839 to 2.347

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Immediate Introduction of Everolimus—35/89 (39.3%)72/89 (80.9%)
Delayed Introduction of Everolimus—31/92 (33.7%)68/92 (73.9%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventImmediate Introduction of EverolimusDelayed Introduction of Everolimus
Pericardial effusionCardiac disorders12/894/92
Transplant rejectionImmune system disorders7/893/92
Cytomegalovirus infectionInfections and infestations4/896/92
PneumoniaRespiratory, thoracic and mediastinal disorders4/891/92
Wound complicationInjury, poisoning and procedural complications3/891/92
Renal failure acuteRenal and urinary disorders3/891/92
Cytomegalovirus syndromeInfections and infestations0/893/92
Oedema peripheralGeneral disorders2/890/92
Urinary tract infectionsInfections and infestations2/891/92
Renal failureRenal and urinary disorders2/890/92
Most frequent other events
Showing 10 of 161
Most frequent other events
EventImmediate Introduction of EverolimusDelayed Introduction of Everolimus
Pericardial effusionCardiac disorders40/8932/92
Transplant rejectionImmune system disorders28/8923/92
Pleural effusionRespiratory, thoracic and mediastinal disorders18/8925/92
LeukopeniaBlood and lymphatic system disorders16/897/92
HypertensionVascular disorders10/8911/92
HypertriglyceridaemiaMetabolism and nutrition disorders4/8910/92
AnaemiaBlood and lymphatic system disorders9/899/92
Wound complicationInjury, poisoning and procedural complications8/898/92
Urinary tract infectionsInfections and infestations6/893/92
PyrexiaGeneral disorders2/896/92

Baseline characteristics

safety population

Age, Continuous
Age, Continuous(years)Immediate Introduction of EverolimusDelayed Introduction of EverolimusTotal
Mean52.69 ± 10.1552.95 ± 10.1952.82 ± 10.14
Sex: Female, Male
Sex: Female, Male(Participants)Immediate Introduction of EverolimusDelayed Introduction of EverolimusTotal
Female162137
Male7371144
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Immediate Introduction of EverolimusDelayed Introduction of EverolimusTotal
Caucasian8888176
Black011
Other134
Weight
Weight(kilograms)Immediate Introduction of EverolimusDelayed Introduction of EverolimusTotal
Mean74.38 ± 12.5071.18 ± 12.7572.76 ± 12.70
Height
Height(centimeters)Immediate Introduction of EverolimusDelayed Introduction of EverolimusTotal
Mean170.80 ± 7.69170.10 ± 8.03170.44 ± 7.85
Calculated BMI
Calculated BMI(kg/m2*)Immediate Introduction of EverolimusDelayed Introduction of EverolimusTotal
Mean25.44 ± 3.6524.48 ± 3.3324.95 ± 3.52
08

Study locations

12 sites
  • Novartis Investigative Site
    Bari, BA 70124, Italy
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Cagliari, CA 09134, Italy
  • Novartis Investigative Site
    Milano, MI 20162, Italy
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
  • Novartis Investigative Site
    Roma, RM 00152, Italy
  • Novartis Investigative Site
    Siena, SI 53100, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Udine, UD 33100, Italy
  • Novartis Investigative Site
    Verona, VR 37126, Italy
  • Novartis Investigative Site
    Napoli, 80131, Italy
09

References and documents

Publications

  • Potena L, Pellegrini C, Grigioni F, Amarelli C, Livi U, Maccherini M, Masciocco G, Faggian G, Lilla Della Monica P, Gerosa G, Marraudino N, Corda M, Boffini M; EVERHEART Investigators. Optimizing the Safety Profile of Everolimus by Delayed Initiation in De Novo Heart Transplant Recipients: Results of the Prospective Randomized Study EVERHEART. Transplantation. 2018 Mar;102(3):493-501. doi: 10.1097/TP.0000000000001945. PubMed 28930797 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2009
First posted
Nov 20, 2009
Start
Sep 2009
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Dec 18, 2014
Last update
Jan 12, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01017029
Responsible party
Sponsor
First posted
Nov 20, 2009
Start date
Sep 2009
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Dec 18, 2014
Last update
Jan 12, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mycophenolic Acid · Everolimus

Start the discussion